About HKTDC | Media Room | Contact HKTDC | Wish List Wish List () | My HKTDC |
繁體 简体
Save As PDF Print this page
Qzone

Compulsory Re-branding Looms for Designated Chinese Patent Medicines

The China Food and Drug Administration (CFDA) has issued new guidelines designed to standardise the generic names of Chinese patent medicines, with several such products likely to be obliged to change their branding/nomenclature.

In particular, three instances have been identified where brand/generic names must be altered in order to comply with the new regulations:

  1. Any instances where the name represents an obvious exaggeration of a product’s curative properties to the extent that doctors and patients could be misled
  2.  Any instance where a product’s name is deemed to be unscientific, vulgar or to have clear references to superstitious practices or beliefs
  3.  All instances where medicines have a variety of names but the same content/efficacy or when a number of medicinal products have the same/similar names but different content/efficacy

In the case of patent medicines sold under location-specific branding, given names, family names or several popular generic terms (including bao/treasure, jing/essence and ling/wonder), the original name may be retained as long as it can be demonstrated that such branding is well-established and familiar to consumers.

For further details (in Chinese), please refer to the following links:

Circular of the CFDA on Issuing the Technical Guidelines on the Naming of Generic Names of Chinese Patent Medicines (No. 188 [2017])

CFDA Issues Technical Guidelines on the Naming of Generic Names of Chinese Patent Medicines

Content provided by Picture: HKTDC Research
Comments (0)
Shows local time in Hong Kong (GMT+8 hours)

HKTDC welcomes your views. Please stay on topic and be respectful of other readers.
Review our Comment Policy

*Add a comment (up to 5,000 characters)